Germany’s Merck slammed in connection with formal French inquiry
According to reports, the French court is investigating in Germany Merck KGaA MKKGYsaying the company provided misleading information regarding its thyroid drug product Levothyrox.
According to reports, the French court is investigating in Germany Merck KGaA MKKGYsaying the company provided misleading information regarding its thyroid drug product Levothyrox.
NEW ORLEANS, Oct. 18, 2022 (GLOBE NEWSWIRE) — Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Louisiana Attorney General Charles C. Foti, Jr.,
NEW ORLEANS, Oct. 18, 2022 (GLOBE NEWSWIRE) — Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Louisiana Attorney General Charles C. Foti, Jr.,
Have you lost money investing in Palantir Technologies? If yes, please visit us Class action lawsuit brought by shareholders of Palantir Technologies or contact Peter
Have you lost money investing in Palantir Technologies? If yes, please visit us Class action lawsuit brought by shareholders of Palantir Technologies or contact Peter
SAN FRANCISCO, Oct. 17, 2022 (GLOBE NEWSWIRE) — Hagens Berman calls for Sema4 Holdings Corp. SMFR Investors who have suffered significant losses Submit your losses
PHILADELPHIA, Oct. 16, 2022 (GLOBE NEWSWIRE) — Kaskela Law LLC announces that it is investigating Athira Pharma, Inc. (“Athira” or the “Company”) (NASDAQ: ATHA) on
SAN FRANCISCO, Oct. 16, 2022 (GLOBE NEWSWIRE) — Hagens Berman is urging Coupang, Inc. CPNG Investors who bought shares as part of the company’s IPO
SAN FRANCISCO, Oct. 16, 2022 (GLOBE NEWSWIRE) — Hagens Berman calls on Co-Diagnostics, Inc. CODX Investors who have suffered significant losses Submit your losses now.
SAN FRANCISCO, Oct. 16, 2022 (GLOBE NEWSWIRE) — Hagens Berman calls on Co-Diagnostics, Inc. (NASDAQ:CODX) Investors who have suffered significant losses Submit your losses now.
SAN FRANCISCO, Oct. 16, 2022 (GLOBE NEWSWIRE) — Hagens Berman is urging Coupang, Inc. (NYSE:CPNG) Investors who bought shares as part of the company’s IPO
NEW YORK, Oct. 14, 2022 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors in Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”)
According to reports, the French court is investigating in Germany Merck KGaA MKKGYsaying the company provided misleading information regarding its thyroid drug product Levothyrox.
NEW ORLEANS, Oct. 18, 2022 (GLOBE NEWSWIRE) — Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Louisiana Attorney General Charles C. Foti, Jr.,
NEW ORLEANS, Oct. 18, 2022 (GLOBE NEWSWIRE) — Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Louisiana Attorney General Charles C. Foti, Jr.,
Have you lost money investing in Palantir Technologies? If yes, please visit us Class action lawsuit brought by shareholders of Palantir Technologies or contact Peter
Have you lost money investing in Palantir Technologies? If yes, please visit us Class action lawsuit brought by shareholders of Palantir Technologies or contact Peter
SAN FRANCISCO, Oct. 17, 2022 (GLOBE NEWSWIRE) — Hagens Berman calls for Sema4 Holdings Corp. SMFR Investors who have suffered significant losses Submit your losses
PHILADELPHIA, Oct. 16, 2022 (GLOBE NEWSWIRE) — Kaskela Law LLC announces that it is investigating Athira Pharma, Inc. (“Athira” or the “Company”) (NASDAQ: ATHA) on
SAN FRANCISCO, Oct. 16, 2022 (GLOBE NEWSWIRE) — Hagens Berman is urging Coupang, Inc. CPNG Investors who bought shares as part of the company’s IPO
SAN FRANCISCO, Oct. 16, 2022 (GLOBE NEWSWIRE) — Hagens Berman calls on Co-Diagnostics, Inc. CODX Investors who have suffered significant losses Submit your losses now.
SAN FRANCISCO, Oct. 16, 2022 (GLOBE NEWSWIRE) — Hagens Berman calls on Co-Diagnostics, Inc. (NASDAQ:CODX) Investors who have suffered significant losses Submit your losses now.
SAN FRANCISCO, Oct. 16, 2022 (GLOBE NEWSWIRE) — Hagens Berman is urging Coupang, Inc. (NYSE:CPNG) Investors who bought shares as part of the company’s IPO
NEW YORK, Oct. 14, 2022 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors in Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”)